ERBB2 and metastatic neoplasm: Of significance, patient 5 presented with HER2 negative primary and metastatic disease but gain of the region containing ERBB2 was detected in 5/9 cfDNA samples and gain or amplifcation was detected in 5/6 CTCs spanning 3 time points (Supp Table 10).